Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis

Objective Fibrocytes are collagen‐producing leukocytes that accumulate in patients with systemic sclerosis (SSc; scleroderma)–related interstitial lung disease (ILD) via unknown mechanisms that have been associated with altered expression of neuroimmune proteins. The extracellular matrix (ECM) influ...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 5; pp. 1251 - 1261
Main Authors Sun, Huanxing, Zhu, Yangyang, Pan, Hongyi, Chen, Xiaosong, Balestrini, Jenna L., Lam, TuKiet T., Kanyo, Jean E., Eichmann, Anne, Gulati, Mridu, Fares, Wassim H., Bai, Hanwen, Feghali‐Bostwick, Carol A., Gan, Ye, Peng, Xueyan, Moore, Meagan W., White, Eric S., Sava, Parid, Gonzalez, Anjelica L., Cheng, Yuwei, Niklason, Laura E., Herzog, Erica L.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective Fibrocytes are collagen‐producing leukocytes that accumulate in patients with systemic sclerosis (SSc; scleroderma)–related interstitial lung disease (ILD) via unknown mechanisms that have been associated with altered expression of neuroimmune proteins. The extracellular matrix (ECM) influences cellular phenotypes. However, a relationship between the lung ECM and fibrocytes in SSc has not been explored. The aim of this study was to use a novel translational platform based on decellularized human lungs to determine whether the lung ECM of patients with scleroderma controls the development of fibrocytes from peripheral blood mononuclear cells. Methods We performed biomechanical evaluation of decellularized scaffolds prepared from lung explants from healthy control subjects and patients with scleroderma, using tensile testing and biochemical and proteomic analysis. Cells obtained from healthy controls and patients with SSc‐related ILD were cultured on these scaffolds, and CD45+pro‐ColIα1+ cells meeting the criteria for fibrocytes were quantified. The contribution of the neuromolecule netrin‐1 to fibrosis was assessed using neutralizing antibodies in this system and by administering bleomycin via inhalation to netrin‐1+/− mice. Results Compared with control lung scaffolds, lung scaffolds from patients with SSc‐related ILD showed aberrant anatomy, enhanced stiffness, and abnormal ECM composition. Culture of control cells in lung scaffolds from patients with SSc‐related ILD increased production of pro‐ColIα1+ cells, which was stimulated by enhanced stiffness and abnormal ECM composition. Cells from patients with SSc‐related ILD demonstrated increased pro‐ColIα1 responsiveness to lung scaffolds from scleroderma patients but not enhanced stiffness. Enhanced detection of netrin‐1–expressing CD14low cells in patients with SSc‐related ILD was observed, and antibody‐mediated netrin‐1 neutralization attenuated detection of CD45+pro‐ColIα1+ cells in all settings. Netrin‐1+/− mice were protected against bleomycin‐induced lung fibrosis and fibrocyte accumulation. Conclusion Factors present in the lung matrices of patients with scleroderma regulate fibrocyte accumulation via a netrin‐1–dependent pathway. Netrin‐1 regulates bleomycin‐induced pulmonary fibrosis in mice. Netrin‐1 might be a novel therapeutic target in SSc‐related ILD.
Bibliography:Dr. Niklason owns stock or stock options in Humacyte.
Drs. Sun, Zhu, and Pan contributed equally to this work.
Dr. White has received consulting fees and/or honoraria from Centocor, Genentech, Bristol‐Myers Squibb, Fibrogen, Boehringer Ingelheim, and Mallinckrodt (less than $10,000 each) and honoraria for advisory board service from Boehringer Ingelheim, Élan Pharmaceuticals, Kadmon Corporation, and Oncothyreon (less than $10,000 each).
Supported by the NIH (grants HL‐109033, U01‐HL‐111016, UL1‐RR‐024153, UL1‐TR‐000005, P30‐AR‐061271, and K24‐AR‐060297 and a Clinical and Translational Science Awards [CTSA] Consortium Sharing Partnership for Innovative Research in Translation [SPIRiT] award from Yale University and the University of Pittsburgh). The mass spectrometry instrument was funded by the NIH (grant SIG‐RR‐031795 to Yale University).
Dr. Herzog has received consulting fees from Boehringer Ingelheim and Pfizer (less than $10,000 each).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2326-5191
2326-5205
DOI:10.1002/art.39575